Aziz Burgy

The Skinny Line Between Possible And Plausible

Squires Again Broadens Discretion For Post-Grant Proceedings

Back To The Well: FDA's Draft Guidance On New Clinical Investigation Exclusivity

Entresto Trade Dress Dispute: No Injunctive Relief For Novartis

Federal Circuit Holds Generic's Hatch-Waxman Litigation Expenses Deductible

Compounding Problems: Recent Decisions On Tirzepatide Highlight Interplay Between FDA Anti-Compounding Enforcement And Private Intellectual Property Rights

Pounding The Compounders: FDA's "No Compound" Lists

Federal Circuit Provides Useful Guidance On Skinny Label Claims

Going Global On Polymorphs

Crossing The Blurred Line Between Brands And Generics

Cost Of Hatch-Waxman Litigation Decreases (Via Tax Deduction)